ORIGINAL ARTICLE

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

A. Blauvelt,1,* K.A. Papp,2 H. Sofen,3 M. Augustin,4 G. Yosipovitch,5 N. Katoh,6 U. Mrowietz,7 M. Ohtsuki,8 Y. Poulin,9,10 D. Shrom,11 R. Burge,11 K. See,11 L. Mallbris,11 K.B. Gordon12
1Oregon Medical Research Center, Portland, OR, USA
2Probity Medical Research and K. Papp Clinical Research, Waterloo, ON, Canada
3Department of Medicine (Dermatology), David Geffen School of Medicine, Los Angeles, CA, USA
4Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Hamburg, Germany
5Department of Dermatology, Miller School of Medicine, University of Miami, Miami, FL, USA
6Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan
7Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany
8Department of Dermatology, Jichi Medical University, Shimotsuke, Tochigi, Japan
9Department of Medicine, Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec, QC, Canada
10Centre de Recherche Dermatologique du Québec Métropolitain, Quebec, QC, Canada
11EI Lilly and Company, Indianapolis, IN, USA
12Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
*Correspondence: A. Blauvelt. E-mail: ABlauvelt@OregonMedicalResearch.com

Abstract

Background Continuous treatment is recommended for patients with moderate-to-severe psoriasis; however, treatment may need to be interrupted in routine clinical practice.

Objective To assess outcomes in patients continuously treated with ixekizumab versus those who interrupted therapy and were subsequently retreated with ixekizumab (IXE).

Methods This analysis used data pooled from two phase 3 trials, UNCOVER-1 and UNCOVER-2. Patients were randomized to placebo (PBO), IXE every 4 (Q4W) or IXE every 2 weeks (Q2W) for 12 weeks. Patients with a static Physician’s Global Assessment (sPGA) 0, 1 at Week 12 were rerandomized to IXEQ4W, IXE every 12 weeks (not presented) or PBO. We examined outcomes in patients who were continuously treated (IXEQ2W/IXEQ4W; IXEQ4W/IXEQ4W) or withdrawn (IXEQ4W/PBO; IXEQ4W/PBO), and in patients who were withdrawn and retreated with IXEQ4W for 24 weeks after disease relapse (sPGA ≥3).

Results A total of 1226 treated patients achieved an sPGA 0, 1 at Week 12 and entered the maintenance phase; of these patients, 402 and 416 were rerandomized to PBO and IXEQ4W, respectively. Among patients interrupting treatment, 157 (82.2%) of IXEQ4W/PBO and 176 (83.4%) of IXEQ2W/PBO had an sPGA ≥3 by Week 60; median time to relapse was approximately 20 weeks irrespective of induction dose. At Week 60, continuously treated patients maintained high levels of PASI and sPGA responses (90.0% PASI 75 IXEQ2W/IXEQ4W; 81.9% sPGA 0, 1 IXEQ2W/IXEQ4W, non-responder imputation). After 24 weeks of retreatment with IXEQ4W (IXEQ2W/PBO/IXEQ4W and IXEQ4W/PBO/IXEQ4W), 87.0% (107 of 123) and 95.1% (97 of 102) (observed), respectively, of patients recaptured PASI 75 and 70.7% (104 of 147) and 82.3% (107 of 130) (observed) recaptured an sPGA 0, 1. Overall, adverse events in continuously treated and retreated patients were comparable.

Conclusion High levels of response were sustained with continuous ixekizumab treatment through 60 weeks. Most patients who were withdrawn experienced disease relapse, and most of those patients recaptured response after 24 weeks of retreatment.

Received: 23 September 2016; Accepted: 13 January 2017

Conflicts of interest A. Blauvelt has received honoraria and clinical study fees from Eli Lilly and Company for scientific consulting, speaking and performing clinical study work. He has also served as a scientific adviser and clinical study investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Genentech, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Sandoz, Sanofi Genzyme, Sun, UCB and Valeant.
K.A. Papp serves as a consultant for/is a speaker bureau member of/received clinical research grants from/
received honoraria from/is an advisory board member of AbbVie, Amgen, Eli Lilly and Company, Janssen, Merck,
Sharp and Dohme, Novartis and Pfizer. He is a consultant for/speaker bureau member/received clinical research
grants from/is an advisory board member of Astellas. He is a speaker bureau member/ received clinical research
grants from/received honoraria from Galderma. He is a consultant for/received honoraria from/an advisory board
member of Baxter. He is a consultant for/received clinical research grants from/received honoraria from/is an
advisory board member of Boehringer Ingelheim, Celgene, Merck-Serono, UCB and Valeant. He is a consultant
for/received honoraria from Akros, Cipher, Forward Pharma, Funxional Therapeutics, Lypanosys, Mitsubishi
Pharma and Vertex. He is a consultant for/ received clinical research grant from/received honoraria from Kyowa
Hakko Kirin and Takeda. He is a consultant for/received clinical research grants from Bristol Myers Squibb,
Dermira, and LEO Pharma. He is a consultant 7 for Akesis, AstraZeneca, Artax, Can-Fite, Ferring
Pharmaceuticals, Formycon, Genentech, Genexion, Genzyme, Gilead, Meiji Seika Pharma, Merck Serono, Mylan,
Pan Genetics, Regeneron, Johnson and Johnson, and Roche. He is a consultant for/an advisory board member
of Sanofi-Aventis. He received clinical research grants from Allergan, Anacor, Celtic, Dow Pharma,
Medimmune and Stiefel. He is a consultant for/received clinical research grants from Baxalta. He received
honoraria from Wyeth. He serves as a scientific officer for AbbVie and Anacor. He is on the steering committee
of AbbVie, Celgene, Eli Lilly and Company, Forward Pharma, Janssen, Kyowa Hakko Kirin, Merck Sharp and
Dohme, Novartis, Pfizer, Regeneron, and Merck-Serono.
H. Sofen has been a paid consultant and clinical investigator of Eli Lilly and Company. He is an investigator and
consultant for Novartis, Janssen, Celgene, Pfizer, Amgen, Sun Pharma, Merck, AbbVie and Boehringer
Ingelheim.
M. Augustin has served as consultant to or paid speaker for 8 clinical trials sponsored by companies that
manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Biogen, Boehringer
Ingelheim, Celgene, Centocor, Eli Lilly and Company, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD,
Novartis, Pfizer, UCB and Xenoprot.
G. Yosipovitch serves as consultant and received honoraria as member of scientific advisory board of Eli Lilly and
Company, Celgene, TREDI, Sanofi-Aventis, Creabilis, Chugai, Opko, TREVI, Creabilis, Pfizer. He serves as a
clinical investigator for Allergan and Genentech and is funded by GSK/Stiefel and LEO Foundation.
N. Katoh has received honoraria as consultant and/or advisory board member and/or acted as paid speaker and/
or participated in clinical trials sponsored by Eli Lilly and Company, Celgene, Maruho, Mitsubishi Tanabe,
Novartis and Sanofi.
U. Mrowietz has been an advisor and/or received speaker honoraria and/or received grants and/or participated in
clinical trials of the following companies: Abbott/AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer
Ingelheim, Celgene, Centocor, Eli Lilly and Company, Foamix, Forward Pharma, Janssen, LEO Pharma, Medac,
MSD, Milltenyi Biotec, Novartis, Pfizer, VBL, Xenoprot.
M. Ohtsuki has received honoraria as consultant and/or advisory board member and/or acted as paid speaker and/or
participated in clinical trials sponsored by Eli Lilly and Company, AbbVie, Boehringer Ingelheim, Celgene,
Eisai, Janssen, Kyowa-Kirin, LEO Pharma, Maruho, Novartis, Pfizer and Mitsubishi Tanabe.
Y. Poulin received research grants and advisory board honoraria from Eli Lilly and Company. He received
research grants from other sponsors, including AbbVie, Amgen, Baxter, Boehringer Ingelheim, Bristol Myers
Squibb, Celgene, Centocor/ Janssen, EMD Serono, Galderma, GSK, LEO Pharma, Merck, Novartis, Pfizer,
Takeda, UCB Pharma. He served on advisory boards for AbbVie, Amgen and Janssen and was on the speaker’s
bureau of AbbVie, Amgen, Celgene, GSK-Stiefel and Janssen.
K.B. Gordon has received research support from Eli Lilly and Company, AbbVie, Amgen, Boehringer Ingelheim,
Celgene, Dermira, Janssen. He has received honoraria from Eli Lilly and Company, AbbVie, Amgen, Boehringer
Ingelheim, Celgene, Dermira, Janssen, Novartis and Pfizer.
D. Shrom, R. Burge, K. See and L. Mallbris are full-time employees of Eli Lilly and Company and own stock.

**Funding sources**

This work was funded by Eli Lilly and Company.
Introduction

The treatment of psoriasis, an incurable disease, has focused on long-term reduction in the severity and extent of disease. Hence, continuous therapy has been recommended for optimal long-term management of moderate-to-severe psoriasis. However, there are reasons why treatment interruption followed by retreatment with the same drug is required. These may include infection, pregnancy and issues such as compliance, drug holidays and loss of insurance coverage. The duration of remission following treatment withdrawal is variable, perhaps because of mechanism of action and pharmacokinetics of specific drugs, the natural course of the disease and the definition of relapse.

When oral and biologic systemic treatments are interrupted, psoriasis plaques invariably reappear, and reduced efficacy is often observed upon re-treatment. Although loss of response or suboptimal ability to recapture response to biologics has been suggested to be attributed to development of neutralizing antibodies (nADA), this does not explain lack of recapture in the subgroup of patients treated with small molecules, which are unlikely to induce nADA. In this regard, the fluctuating nature of the disease and optimal strategies for timing of interruption and retreatment have been discussed. Thus, it is important to understand the probability and timing of disease recurrence and return of symptoms. It is also critical to know whether retreatment leads to recapture of clinical response.

I.xekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. It has been studied in three randomized, placebo-controlled, double-blind clinical trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3) and has demonstrated high skin clearance of plaque psoriasis at Week 12, with response maintenance for 60 weeks in a majority of patients in all three trials. We report a pooled analysis of two phase 3 ixekizumab trials (UNCOVER-1 and UNCOVER-2) with treatment and interruption/retreatment periods; this analysis evaluates safety and efficacy outcomes among patients who were continuously treated, withdrawn from therapy, or withdrawn and retreated after experiencing disease worsening.

Methods

Study design and patients

UNCOVER-1 (NCT01474512) and UNCOVER-2 (NCT01597245) are multicentre, phase 3, randomized, double-blind, placebo-controlled trials. Patients ≥18 years with chronic plaque psoriasis ≥6 months prior to randomization were eligible. At screening and baseline, eligible patients had a static Physician’s Global Assessment (sPGA) score ≥3; Psoriasis Area and Severity Index (PASI) ≥12; and ≥10% affected body surface area. Trials were compliant with applicable guidelines. Ethical review boards approved protocols and informed consent forms. Signed informed consent was obtained prior to study-related procedures.

Study design and treatment

In UNCOVER-1, patients were randomized 1:1:1 to receive subcutaneous ixekizumab 80 mg every 2 weeks (IXEQ2W), ixekizumab 80 mg every 4 weeks (IXEQ4W) (each with a 160 mg starting dose) or placebo (PBO) for 12 weeks (Fig. 1). Randomization was stratified by geographic region (North America or other), previous non-biologic systemic therapy (inadequate response to, intolerance to or contraindication to <3 or ≥3 conventional systemic therapies) and weight category (<100 kg or ≥100 kg). In UNCOVER-2, patients were randomized 2:2:2:1 to receive IXEQ2W, IXEQ4W (each with a 160 mg starting dose), etanercept 50 mg twice weekly or placebo for 12 weeks (Fig. 1). Randomization was stratified by centre.

In both trials, the 12-week induction period was followed by a 48-week randomized withdrawal (maintenance) period (weeks 12–60), whereby ixekizumab responders at Week 12 (sPGA = 0 or 1) were rerandomized (1:1:1) to receive subcutaneous placebo, IXEQ4W or ixekizumab 80 mg every 12 weeks (IXEQ12W) (Fig. 1). At Week 60, all patients receiving IXEQ4W entered the long-term extension period and continued to receive IXEQ4W. Visits occurred every 4 weeks during the maintenance period and every 12 weeks during the long-term extension period. Patients who were rerandomized to IXEQ12W were not included in these analyses. Patients in any group who experienced disease worsening defined by an sPGA ≥3 (relapse) during the maintenance period received open-label IXEQ4W.

Relapse and retreatment criteria were chosen in consultation with, and agreed to by, regulatory authorities. Cut-offs were chosen to clearly identify changes while minimizing exposure to placebo.

Objective, populations and outcomes

The objective was to evaluate outcomes in patients who were continuously treated with ixekizumab (Week 12 responders who were rerandomized to IXEQ4W) or withdrawn from treatment (Week 12 responders who were rerandomized to placebo) during the 48-week maintenance period. Additionally, we evaluated safety and efficacy outcomes in patients who were retreated with IXEQ4W after experiencing disease worsening during withdrawal.

In each population, mean PASI and Itch Numeric Rating Scale (NRS) were evaluated. Additionally, the proportions of patients with ≥75%, ≥90% and 100% improvement in PASI over baseline (PASI 75, PASI 90, PASI 100) or sPGA 0, and sPGA 0, 1 were evaluated. The PASI is a physician-reported measure combining lesion severity and affected area into a score ranging from 0 (no disease) to 72 (maximal disease). The physician-reported sPGA rated lesions as follows: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. The Itch NRS is a patient-reported outcome whereby patients rate their itch on a numeric scale of 0 (no itch) to 10 (worst itch imaginable) in a 24-h period.
Among continuously treated patients and withdrawn patients, response rates were summarized through the maintenance period (weeks 12–60). In addition, mean PASI and Itch NRS were calculated for these groups for the induction period and maintenance periods (weeks 0–60). Patients in the continuously treated group who experienced disease worsening continued to receive IXEQ4W (open label) per protocol, and, therefore, data for these patients were analysed in the continuously treated group through Week 60 irrespective of having prior sPGA ≥3. Patients in the withdrawal group who experienced disease worsening at one visit received open-label IXEQ4W. These patients were considered non-responders at all subsequent visits; data for these patients were not analysed in the withdrawal group after the time of relapse.

Among patients who were withdrawn and retreated, the time of sPGA ≥3 was considered retreatment Week 0. Response rates were summarized over time from retreatment Week 0 through retreatment Week 24. sPGA 0,1 response rates were calculated for all patients who experienced disease worsening (sPGA ≥3). PASI 75, PASI 90 and PASI 100 response rates were calculated for patients who had sPGA ≥3 and did not have a PASI 75 at the time of sPGA ≥3; the baseline PASI was used in the calculations. Mean PASI and Itch NRS were calculated for 24 weeks of retreatment. Although the maintenance period ended at Week 60, additional data from the long-term extension period were used up to and including Week 84 to allow for 24 weeks of retreatment. At the time of this database lock, all patients completed Week 60. Not all retreated patients had the opportunity to receive 24 weeks of retreatment.

Adverse events (AEs) were classified based on the Medical Dictionary for Regulatory Activities version 18.0. A treatment-emergent AE (TEAE) was defined as an event that first occurred or worsened in severity in the maintenance period; all events starting or worsening in the relapse period were counted in the retreatment period and were not included in the maintenance period. Exposure-adjusted incidence rates (IRs) for TEAEs report the number of unique patients with a specific event per 100 patient-years of exposure; this calculation uses the sum of all patients’ time (in 100 years) of exposure during the treatment period. For each patient, the entire time during the treatment period was counted as exposure time. An event was only counted once if it occurred multiple times in each patient.

Statistical analyses
All patients were analysed per assigned treatment in UNCOVER-1 and UNCOVER-2, including the re-assignment of IXEQ4W to relapsed patients. Categorical efficacy measures were compared using Cochran–Mantel–Haenszel (CMH) tests stratified by study. Categorical variables were analysed using observed data as well as using non-responder imputation (NRI), which imputes missing values as non-responders for both the
continuously treated and interrupted patients, for Week 60 comparisons. Continuous PASI measures were analysed using an analysis of covariance model on observed values with main effects for treatment and study, and baseline as a covariate. The median time to relapse is the simple arithmetic median time of relapse for each patient from the start of maintenance to first relapse. Safety analyses were conducted on Week 12 sPGA 0, 1 responders entering the maintenance phase. Adverse events are displayed as counts, percentages and IRs for each group.

The sPGA 0, sPGA 0,1, PASI 75, PASI 90 and PASI 100 response rates and the associated 95% confidence intervals (CI) were computed for treatment groups using the Wilson score method without continuity correction and displayed across the maintenance and retreatment periods. For sPGA and PASI outcomes, a comparison of response rates at Week 60 was performed to compare continuous treatment to interrupted treatment (IXEQ4W/IXEQ4W versus IXEQ4W/PBO and IXEQ2W/IXEQ4W versus IXEQ2W/PBO) using a CMH test stratified by study.

Serum samples
Serum samples collected through Week 60 were analysed for antidrug antibodies (ADA) to ixekizumab. Samples were collected at weeks 0, 4, 8 and 12, then every 12 weeks to Week 60 and then every 24 weeks thereafter. Antidrug antibodies were detected using a competitive ligand-binding format.16

Results
Demographics and disposition
Overall, 1226 ixekizumab-treated patients in UNCOVER-1 and UNCOVER-2 achieved an sPGA of 0 or 1 by Week 12 and

| Table 1 Patient disposition from study treatment: maintenance period (UNCOVER-1 and UNCOVER-2) |
|---------------------------------------------------------------|
| IXEQ2W/PBO | IXEQ2W/IXEQ4W | IXEQ4W/PBO | IXEQ4W/IXEQ4W |
| N = 211 | N = 221 | N = 191 | N = 195 |
| Completed Period, n (%) | 23 (10.9) | 184 (83.3) | 18 (9.4) | 143 (73.3) |
| Relapsed, n (%) | 176 (83.4) | 27 (12.2) | 157 (82.2) | 36 (18.5) |
| Discontinued, n (%) | 11 (5.2) | 11 (5.0) | 16 (8.4) | 17 (8.7) |
| Adverse event | 2 (0.9) | 6 (2.7) | 6 (3.1) | 7 (3.6) |
| Subject decision | 3 (1.4) | 2 (0.9) | 6 (3.1) | 4 (2.1) |
| Lost to follow-up | 3 (1.4) | 1 (0.5) | 1 (0.5) | 1 (0.5) |
| Death | 0 | 1 (0.5) | 0 | 1 (0.5) |
| Investigator decision | 0 | 1 (0.5) | 0 | 1 (0.5) |
| Lack of efficacy | 1 (0.5) | 0 | 0 | 1 (0.5) |
| Protocol violation | 1 (0.5) | 0 | 1 (0.5) | 0 |

IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; N, population size; n, number in group; PBO, placebo.

| Table 2 Baseline demographics: maintenance period (UNCOVER-1 and UNCOVER-2) |
|---------------------------------------------------------------|
| Characteristic | IXEQ2W/PBO | IXEQ2W/IXEQ4W | IXEQ4W/PBO | IXEQ4W/IXEQ4W |
| N = 211 | N = 221 | N = 191 | N = 195 |
| Age mean (SD), years | 44.5 (12.6) | 43.5 (13.0) | 44.0 (13.2) | 44.1 (13.2) |
| Male, n (%) | 140 (66.4) | 151 (68.3) | 124 (64.9) | 136 (69.7) |
| Race, n (%)* | | | | |
| Asian | 8 (3.8) | 8 (3.6) | 9 (4.7) | 9 (4.6) |
| Black or African American | 3 (1.4) | 3 (1.4) | 7 (3.7) | 2 (1.0) |
| White | 198 (93.8) | 208 (94.1) | 172 (90.5) | 184 (94.4) |
| Other or multiple | 2 (0.9) | 2 (0.9) | 2 (1.0) | 0 |
| BMI mean, kg/m² (SD)* | 30.1 (6.1) | 30.2 (7.0) | 30.1 (6.8) | 30.1 (6.5) |
| Duration of psoriasis symptoms mean, years (SD) | 19.7 (12.2) | 18.4 (12.1) | 18.4 (10.7) | 20.4 (13.1) |
| BSA involved, % (SD) | 26.7 (17.6) | 27.1 (16.5) | 26.0 (15.2) | 25.8 (14.8) |
| Itch NRS score, mean (SD)† | 6.8 (2.5) | 6.5 (2.6) | 6.8 (2.6) | 6.6 (2.7) |
| PASI score, mean (SD) | 19.8 (7.9) | 19.4 (7.3) | 19.4 (6.2) | 19.3 (6.8) |
| sPGA score, mean (SD) | 3.5 (0.6) | 3.5 (0.6) | 3.5 (0.6) | 3.6 (0.6) |

BSA, body surface area; BMI, body mass index; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; N, population size; n, number in group; NRS, Numeric Rating Scale; PASI, Psoriasis Area and Severity Index; PBO, placebo, sPGA, static Physician’s Global Assessment; SD, standard deviation.

* n = 190 for IXEQ4W/PBO.
† n = 193 for IXEQ4W/IXEQ4W.
Withdrawal and continuous treatment

At Week 60 using NRI, 74.4% of patients with IXEQ4W induction dose and randomized to IXEQ4W continuous treatment had an sPGA 0, 1 compared to 6.3% of patients randomized to placebo during maintenance ($P < 0.001$; continuous vs. withdrawal of treatment) (Fig. 2a,b).

High response rates were also attained or maintained through Week 60 for PASI 75, PASI 90 and PASI 100 for both IXEQ2W/IXEQ4W and IXEQ4W/IXEQ4W groups compared to the withdrawal group (Fig. 2).

Among patients who were withdrawn from therapy, 176 (83.4%) of IXEQ2W/PBO and 157 (82.2%) of IXEQ4W/PBO had disease worsening (sPGA $\geq 3$) by Week 60; median time to relapse (sPGA $\geq 3$) was 20.4 weeks for IXEQ2W/PBO and 20.1 weeks for IXEQ4W/PBO. In addition, 149 of 176 (IXEQ2W/PBO) and 124 of 157 (IXEQ4W/PBO) patients had disease worsening with a loss of the initial PASI 75 at the time of disease worsening.

Among patients who interrupted ixekizumab treatment, mean (standard deviation [SD]) PASI increased gradually from Week 12 (0.9 [1.25] IXEQ2W/PBO; 0.9 [1.24] IXEQ4W/PBO) to relapse (9.2 [5.00] IXEQ2W/PBO; 7.9 [4.34] IXEQ4W/PBO) (Fig. 3a). In contrast, low mean [SD] PASI was sustained from Week 12 (1.1 [1.44] IXEQ2W/IXEQ4W; 1.2 [1.66] IXEQ4W/IXEQ4W) through Week 60 (1.0 [2.46] IXEQ2W/IXEQ4W; 1.2 [2.31] IXEQ4W/IXEQ4W) among patients continuing ixekizumab treatment.

Mean Itch NRS scores followed the same trends as PASI (Fig. 3b). In patients interrupted from treatment, mean [SD] Itch NRS scores increased from withdrawal at Week 12 (1.0 [1.37] IXEQ2W/PBO; 1.0 [1.30] IXEQ4W/PBO) to relapse (5.0 [2.75] IXEQ2W/PBO; 4.5 [2.80] IXEQ4W/PBO). In continuously treated patients, however, mean [SD] Itch NRS scores remained mostly constant and low from Week 12 (1.1 [1.46] IXEQ2W/IXEQ4W; 1.0 [1.47] IXEQ4W/IXEQ4W) through Week 60 (0.8 [1.47] IXEQ2W/IXEQ4W; 1.1 [1.91] IXEQ4W/IXEQ4W).

Retreatment period

Among patients who had disease worsening (sPGA $\geq 3$), sPGA 0, 1 responses were recaptured in 70.7% of IXEQ2W/PBO/IXEQ4W- (Fig. 4a) and 82.3% of IXEQ4W/PBO/IXEQ4W-treated patients after 24 weeks of retreatment. Likewise, among those who had disease worsening (sPGA $\geq 3$) and lost the initial PASI 75 response, 87.0% and 95.1% of patients from the IXEQ2W and IXEQ4W induction arms, respectively, recaptured PASI 75 after 24 weeks of retreatment with IXEQ4W (Fig. 4b). Furthermore, 63.4% and 78.4% of these patients, respectively, achieved PASI 90, and 31.7% and 45.1% of these patients, respectively, achieved PASI 100 after 24 weeks of retreatment. Comparable results were observed at Week 12 (Fig. 4). Median time to recapture of PASI 75 and itch was 4.0 weeks for both IXEQ2W and IXEQ4W arms.

With respect to mean PASI, relapsed patients regained clinical improvements in psoriasis as evidenced by reductions in observed mean PASI after 12 and 24 weeks of retreatment relative to relapse (Week 0 of retreatment) (Fig. 3a; observed mean PASI was lower).
[SD] 24 weeks: IXEQ2W/PBO/IXEQ4W: 2.0 [3.22], IXEQ4W/PBO/IXEQ4W: 1.1 [1.78]). Likewise, after 12 and 24 weeks of retreatment, relapsed patients regained improvements in their mean Itch NRS scores (Fig. 3b; observed mean [SD] 24 weeks: IXEQ2W/PBO/IXEQ4W: 1.8 [2.30]; IXEQ4W/PBO/IXEQ4W: 1.3 [1.97]). Generally, itch reduction showed the same pattern as PASI improvements (Fig. 3b).

**Safety**

Generally, the safety profiles of the continuously treated and retreated group were comparable (Table 3); no unexpected types of safety events were observed upon retreatment, compared with initial treatment. The most common TEAEs were nasopharyngitis, upper respiratory infection and sinusitis in continuously treated and retreated patients. Most TEAEs were mild or moderate. Two serious AEs (SAEs) occurred in more than one patient in a treatment arm: fall (two patients each in continuously treated and retreated groups) and osteoarthritis (two patients in continuously treated group); other SAEs were reported in one patient per arm.

Treatment-emergent antidrug antibodies were detected in 42 of 220 (19.1%) of tested continuously treated patients during the entire 60-week treatment period on the recommended dose of IXEQ2W/IXEQ4W, and in 39 of 173
Table 3  Patients with adverse events

|                     | Continuously treated (AE occurring in maintenance regardless of relapse status) | Withdrawal to relapse (AE before relapse or occurring in maintenance period for non-relapsers) | Withdrawn, relapsed and retreated (AEs occurring during retreatment) |
|---------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
|                     | IXEQ2W/Q4W N = 221                                                            | IXEQ4W/Q4W N = 195                                                                          | IXEQ2W/PBO N = 211                                                                 |
|                     |                                                                                 | IXEQ4W/PBO N = 191                                                                          | IXEQ2W/PBO N = 176                                                                 |
|                     |                                                                                 | IXEQ4W/PBO N = 157                                                                          |                                                                                     |
| Total person-years | 189.2                                                                           | 158.1                                                                                       | 101.5                                                                               |
|                     |                                                                                 | 86.8                                                                                       | 74.2                                                                                |
|                     |                                                                                 | 74.2                                                                                       | 62.2                                                                                |
| TEAE, n (%) [IR]    | 175 (79.2) [92.5]                                                              | 156 (80.0) [98.7]                                                                          | 58 (27.5) [57.2]                                                                 |
|                     | 58 (27.5) [57.2]                                                               | 70 (36.6) [80.6]                                                                           | 85 (48.3) [114.5]                                                                |
| Mild                | 84 (38.0) [44.4]                                                              | 55 (28.2) [34.8]                                                                           | 28 (13.3) [27.6]                                                                 |
|                     | 42 (22.0) [48.4]                                                               | 46 (29.3) [73.9]                                                                           |                                                                                     |
| Moderate            | 74 (33.5) [39.1]                                                              | 85 (43.6) [53.8]                                                                           | 24 (11.4) [23.7]                                                                 |
|                     | 25 (13.1) [28.8]                                                               | 38 (21.6) [51.2]                                                                           | 30 (19.1) [48.2]                                                                 |
| Severe              | 17 (7.7) [9.0]                                                                | 16 (8.2) [10.1]                                                                            | 6 (2.8) [5.9]                                                                     |
|                     | 3 (1.6) [3.5]                                                                  | 11 (6.3) [14.8]                                                                            | 2 (1.3) [3.2]                                                                     |

Common TEAEs†, n (%) [IR]

|                     | Nasopharyngitis                  | —                                            | —                                            |
|                     | —                                | —                                            | 15 (8.5) [20.2]                              |
|                     | Upper respiratory infection      | 38 (17.2) [20.1]                             | 44 (22.6) [27.8]                            |
|                     | —                                | 4 (1.9) [3.9]                               | 9 (4.7) [10.4]                              |
|                     | Sinusitis                        | 11 (5.0) [5.8]                              | —                                            |
|                     | —                                | 2 (0.9) [2.0]                               | 1 (0.5) [1.2]                              |
|                     | Arthralgia                       | 13 (5.9) [6.9]                              | —                                            |
|                     | —                                | 6 (2.8) [5.9]                               | 6 (3.1) [6.9]                              |
|                     | Injection-site reaction‡         | 14 (6.3) [7.4]                              | —                                            |
|                     | —                                | 0 (0) [0]                                   | 0 (0) [0]                                   |
|                     | Headache                         | 9 (4.1) [4.8]                               | —                                            |
|                     | —                                | 2 (0.9) [2.0]                               | 1 (0.5) [1.2]                              |
| SAE, n (%) [IR]     | 10 (4.5) [5.3]                   | 18 (8.7) [10.8]                             | 6 (2.8) [5.9]                               |
|                     | —                                | 4 (2.1) [4.6]                               | 6 (3.4) [8.1]                               |
|                     | —                                | 1 (0.6) [1.6]                               | 1 (0.6) [1.6]                               |

Common SAEs, n (%) [IR]§

|                     | Fall                             | —                                            | —                                            |
|                     | —                                | 2 (0.9) [1.1]                               | 0 (0) [0]                                   |
|                     | Osteoarthritis                   | —                                            | —                                            |
|                     | —                                | 2 (1.0) [1.3]                               | 0 (0) [0]                                   |
|                     | Discontinuations of study drug    | 8 (3.6) [4.2]                               | —                                            |
|                     | due to AE (includes death), n (%) [IR] | —                                        | 6 (2.9) [2.0]                               |
|                     | —                                | 6 (3.1) [6.9]                               | 0 (0) [0]                                   |

TEAEs of special interest, n (%) [IR]

|                     | Infection                        | —                                            | —                                            |
|                     | —                                | 131 (59.3) [69.2]                           | 111 (56.9) [70.2]                           |
|                     | Injection-site reactions‡         | —                                            | —                                            |
|                     | —                                | 21 (9.5) [11.1]                             | 16 (8.2) [10.1]                            |
|                     | Cerebro-cardiovascular events     | 8 (3.6) [4.2]                               | —                                            |
|                     | —                                | 3 (1.5) [1.9]                               | 9 (4.5) [5.3]                              |
|                     | Malignancies                     | 1 (0.5) [0.5]                               | —                                            |
|                     | —                                | 2 (0.9) [1.1]                               | 0 (0) [0]                                   |
|                     | Depression                       | 1 (0.5) [0.5]                               | —                                            |
|                     | —                                | 1 (0.5) [1.0]                               | 0 (0) [0]                                   |
|                     | Crohn’s disease                  | 1 (0.5) [0.5]                               | —                                            |
|                     | —                                | 3 (1.4) [3.0]                               | 9 (4.5) [5.3]                              |
|                     | Ulcerative colitis               | 0 (0) [0]                                   | —                                            |
|                     | —                                | 1 (0.5) [0.6]                               | 9 (4.5) [5.3]                              |

AE, adverse event; IR, exposure-adjusted incidence rate; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; N, population size; n, number in group; PBO, placebo; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

*Patients with multiple occurrences of these categories are counted once for each category.
†Occurring in ≥5% of patients in any arm in any group.
‡Preferred term.
§Occurring in ≥2 patients in any arm in any group.
*A composite of several injection-site reaction-related preferred terms.

(22.5%) of patients who withdrew from the recommended dose (IXEQ2W) and restarted treatment upon relapse (sPGA ≥3). Neutralizing antibodies were detected in two patients during re-treatment in this group and in no continuously treated patients. There were no meaningful differences in % PASI improvement upon re-treatment in patients with or without treatment-emergent ADA (Fig. 5).

Discussion
Continuous treatment with ixekizumab provided better and higher maintenance of efficacy up to 60 weeks in patients with moderate-to-severe psoriasis compared to treatment interruption. The low and stable mean PASI in continuously treated patients suggested that continuous therapy is the optimal strategy for sustained skin clearance and relapse avoidance. Continuous ixekizumab treatment enabled patients to have consistent itch reduction, as Itch NRS scores were consistently low during maintenance. When treatment was interrupted, efficacy waned, resulting in higher PASI and itch scores with a median time to relapse of approximately 5 months. Retreatment of patients with ixekizumab after interruption of ixekizumab therapy resulted in substantial improvements with recapture of initial responses for most patients.

In the pooled analysis of UNCOVER-1 and UNCOVER-2 reported here among patients receiving the recommended induction dosing regimen who were withdrawn and relapsed,
As reported for other biologics, however, not all patients regained the same degree of skin clearance upon re-initiation of ixekizumab when compared with initial responses to this drug. Different withdrawal times and strategies may result in different clinical outcomes, and thus, further exploration of ixekizumab retreatment is warranted. Similar investigations on retreatment have been conducted for secukinumab, another IL-17A antagonist. Results have varied depending on the retreatment strategy used. In the SCULPTURE trial, Mrowietz and colleagues used a once-monthly dosing regimen upon retreatment. As reported for other biologics, however, not all patients regained the same degree of skin clearance upon re-initiation of ixekizumab when compared with initial responses to this drug. Different withdrawal times and strategies may result in different clinical outcomes, and thus, further exploration of ixekizumab retreatment is warranted. Similar investigations on retreatment have been conducted for secukinumab, another IL-17A antagonist. Results have varied depending on the retreatment strategy used. In the SCULPTURE trial, Mrowietz and colleagues used a once-monthly dosing regimen upon retreatment.
Continuous vs interrupted ixekizumab

The study designs for UNCOVER-1 and UNCOVER-2 provided rigorous and randomized assessments of the consequences of treatment interruption versus continuous treatment. However, the study is limited in that the treatment interruptions were dictated by design rather than by patient and physician decision as would be the case in clinical practice.

In conclusion, continuous treatment resulted in sustained responses through Week 60, and most patients with an initial response, who were rerandomized to placebo, experienced disease recurrence and increased itching with a median time to relapse of approximately 5 months after stopping drug; most of these patients recaptured their clinical responses within 12 to 24 weeks of retreatment with ixekizumab. The median time to recapture of PASI 75 was 4 weeks. Safety profiles of patients with continuous ixekizumab were comparable with those who interrupted treatment and were retreated, with no increase in ADA. The findings presented here suggest that, if necessary to interrupt therapy during routine clinical practice, retreatment with ixekizumab is safe and effective in most patients.

Acknowledgements
The authors thank Lori Kornberg, PhD, who is a full-time employee of INC Research (Raleigh, NC), for writing support and Missy McKean-Matthews, MS who is a full-time employee of InVentiv Health Clinical (Princeton, NJ), for statistical support.

References
1. Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Dermatol 2013; 38(4 Suppl 78): S63–S70.
2. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE 2012; 7:e33486.
3. Mrowietz U, de Jong EM, Kragballe K et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 438–453.
4. Papp K, Crowley J, Ortonne JP et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434–441.
5. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 2007; 6: 1205–1212.
6. Bissonnette R, Iversen L, Sofen H et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015; 172: 1395–1406.
7. Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol 2015; 29: 468–473.
8. Mrowietz U, Leonardi CI, Girolomoni G G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73: 27–36.
9. Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol 2013; 27: 634–642.
10. Alinea H, Feldman SR. Oral tofacitinib for psoriasis: what happens with interrupted treatment? Br J Dermatol 2015; 172: 1194–1195.
11. Liu L, Lu J, Allan BW et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 2016; 9: 39–50.
12. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New Engl J Med 2016; 375: 345–356.
13. Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541–551.
14. Fredriksson T, Petersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244.
15. Naegeli AN, Flood E, Tucker J, Devlen J, Edison-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54: 715–722.
16. Muram TM, Sloan JH, Chain JS et al. A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution. J Invest Dermatol 2016; 136: 1513–1515.
17. TALTZ-ixekizumab injection. Full Prescribing Information [Internet]. Eli Lilly and Company, Indianapolis, IN. March 2016 [cited July 8, 2016]. URL http://usplilly.com/taltz/taltz.html#pi.
18. Mrowietz U, Papavassiliou C, Leonardi C, Toth D, Thurston HJ. Secukinumab retreatment-as-needed maintenance regimen: efficacy and safety outcomes from the SCULPTURE study. 72nd Annual Meeting of the American Academy of Dermatology, 2014. J Am Acad Dermatol 2014; 70: AB188 [P8229].
19. Blauvelt A, Langley RGB, Szpiewkowski JC et al. Secukinumab withdrawal leads to loss of treatment responses in a majority of subjects with plaque psoriasis with re-treatment resulting in rapid regain of responses: a pooled analysis of two phase 3 trials. 74th Annual Meeting of the American Academy of Dermatology, 2016. J Am Acad Dermatol 2016; 74: AB273 [P3719].